The obesity paradox in metastatic castration-resistant prostate cancer

Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data

(2021) Alberto Martini et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index

(2020) Christine Desmedt et al.   JOURNAL OF CLINICAL ONCOLOGY

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

(2019) Douglas Donnelly et al.   Journal for ImmunoTherapy of Cancer

Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

(2018) Adriana C. Vidal et al.   BJU INTERNATIONAL

Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer

(2018) Jong Soo Lee et al.   JOURNAL OF UROLOGY

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

(2018) Jennifer L McQuade et al.   LANCET ONCOLOGY

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

(2018) Ziming Wang et al.   NATURE MEDICINE

Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity — United States, 2005–2014

(2017) C. Brooke Steele et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations

(2016) Laurence Albiges et al.   JOURNAL OF CLINICAL ONCOLOGY

Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

(2016) A C Vidal et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

(2015) Daniel P Petrylak et al.   LANCET ONCOLOGY

Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review

(2015) Weixin Wu et al.   PLoS One

The obesity paradox: Understanding the effect of obesity on mortality among individuals with cardiovascular disease

(2014) Hailey R. Banack et al.   PREVENTIVE MEDICINE

The “Obesity Paradox” Explained

(2013) Hailey R. Banack et al.   EPIDEMIOLOGY

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

(2013) Ian F Tannock et al.   LANCET ONCOLOGY

Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers

(2012) Anne E. Utech et al.   Journal of Cachexia Sarcopenia and Muscle

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer

(2011) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival

(2010) Paul L. Nguyen et al.   JOURNAL OF CLINICAL ONCOLOGY

The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer

(2008) A J Armstrong et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Obesity Is a Significant Risk Factor for Prostate Cancer at the Time of Biopsy

(2008) Stephen J. Freedland et al.   UROLOGY